fashion -WSS

fashion

author：leisure time 2025-10-02 21:35:55 - browse：42

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： iTeos Therapeutics debuts first data on TIGIT

entertainment

WSS

Being 'nonadherent' patient made me a more empathetic doctor

The wait for US passports is creating travel purgatory and snarling summer plans

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Scientists successfully use ultrasound imaging to map brain activity

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

focus

fashion

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The biotech scorecard for Q3: 15 stock

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Prescription digital therapeutics are key to pharma’s future

DIEP, the 'gold standard' of breast reconstruction, is under threat

Drug cartel violence flares in western Mexico after vigilante leader's killing

Psychedelics group wrestles with new pharma identity

First Opinion Podcast: What happens when kids become caregivers?

explore

Prosthetic arm enables patients to feel the objects they grip

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Use doctors trained outside the U.S. to ease the physician shortage

Prosthetic arm enables patients to feel the objects they grip

Antibiotic resistance nearly killed me, so I'm raising awareness of it

hotspot

entertainment

hotspot

hotspot